• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Adenovirus-vectored ChAdOx1 nCoV-19 vaccine offers a good safety profile and strong immunogenicity against COVID-19 in older adults 

byMichael PratteandTeddy Guo
December 29, 2020
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The ChAdOx1 nCoV-19 vaccine against COVID-19 was well-tolerated overall, with reduced reactogenicity in older adults.

2. The ChAdOx1 nCoV-19 vaccine induced a robust SARS-CoV-2 spike-antibody response and showed similar immunogenicity across all age groups after a boost dose.

Evidence Rating Level: 1 (Excellent)

Study Rundown: As the SARS-CoV-2 virus continues to impact healthcare systems across the world, there is an increasing need for a vaccine. At the time of this article’s writing, there were 48 vaccines currently in development, although none have been licensed. Vaccines utilizing replication-deficient adenoviruses have shown success as vaccine vectors in recent years. The ChAdOx1 nCoV-19 vaccine, which employs such a vector, has shown promising efficacy and safety profiles in rhesus macaques as well as in a phase 1/2 trial in adults aged 18-55 years old. Uncertainty still exists, however, about its efficacy and safety in older adults aged >70 years old, largely considered to be in the highest-risk groups for COVID-19. This ongoing, single-blind phase 2/3 trial was created to evaluate the efficacy and safety profile of the ChAdOx1 nCoV-19 vaccine across all adult age groups (18-70+). Overall, adverse events to the vaccine were modest in all age groups, with a reduced number of events in those aged 70 and above. There was a robust antibody response to the vaccine, which did not vary based on age. Notably, these promising results are consistent with a vaccine against influenza sharing a similar construct, which was successfully developed for adults over 50 years old. An important limitation of this study, however, was that, although it was intended to evaluate the vaccine in older adults, the median age of those older than 70 was only 73-74 years old, which is perhaps not reflective of elderly populations in nursing homes.

Click to read the study in The Lancet

Click to read an accompanying editorial in The Lancet

Relevant Reading: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

RELATED REPORTS

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

In-Depth [randomized controlled trial]: This ongoing single-blind, multicenter, randomized controlled phase 2/3 trial took place at 20 centers across the United Kingdom. Participants were recruited in an age-escalation manner across age groups 18-55, 56-69 and 70+ years old. A total of 560 participants were enrolled into ten different subgroups (stratified by age, single versus two-dose regimen, low dose vs. standard dose cohort and experimental versus control group). The MenACWY vaccine was used as control to maintain masking with adverse events. The primary endpoints were efficacy and safety, with secondary outcomes focusing primarily on older adults aged 56-69 and 70+. Local adverse events were mostly benign and mild-moderate in severity. No severe local adverse events were reported. Overall, fatigue, headache, feverishness and myalgias were the most common systemic adverse events across all age groups, with fewer events reported in adults aged 56+. A general trend towards fewer adverse events as age increased was seen in both dose groups (low vs. standard). Anti-spike antibody titres at 28 days after prime vaccination were similar between those who received the low or standard-dose of ChAdOx1 nCoV-19. However, anti-spike IgG responses at day 28 decreased with increasing age. At 28 days after the boost vaccine, immunogenicity was similar across all two-dose groups, regardless of age or vaccine dose, as demonstrated by the non-significant differences in antibody titres (standard dose groups: median 20,713 arbitrary units [AU]/mL [IQR 13,898-33,550] for 18-55 years; 16 170 AU/mL [IQR 10,233-40,353] for 56-69 years; and  17,561 AU/mL [IQR 9,705-37,796] for ≥70 years).

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ChAdOx1 nCoV-2 vaccineCOVID-19 VaccineSARS-CoV-2vaccine
Previous Post

Lower doses of ketamine shown to be non-inferior for acute pain control in the emergency setting

Next Post

#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

RelatedReports

RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant
Infectious Disease

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

June 22, 2022
Waning Tdap vaccine effectiveness among adolescents
Infectious Disease

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

June 20, 2022
Next Post
#VisualAbstract: Special Report: Vaccines in Development Part 2: Moderna vaccine second to receive emergency use authorization

#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Abnormal preoperative digital brachial index is associated with lower two-year arteriovenous fistula access patency

#VisualAbstract: Low mammographic breast density may be associated with an increased risk of developing severe lymphedema

#VisualAbstract: Low mammographic breast density may be associated with an increased risk of developing severe lymphedema

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous fluid restriction does not improve septic shock outcomes
  • Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
  • Magnetic resonance based preoperative evaluation for perianal fistulas superior to traditional clinical method and improve surgical outcomes [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.